Special Issue

New Formulations for Cancer Therapy Volume II

Message from the Guest Editors

The search for new formulations for cancer therapy to achieve improved bioavailability, efficacy, and safety constitutes the holy grail of anticancer drug research. In the fight against cancer, in recent years, researchers have put tremendous effort into evaluating the potential of drug carriers for this purpose. Noticeably, in the case of chemotherapeutic agents, drug encapsulation within carriers greatly contributes to reducing their frequent non-specific side effects that often lead to treatment discontinuation. Despite several carrier-based formulations achieving clinical translation, promising possibilities to develop second-generation formulations that address unmet advanced cancer-related medical challenges and ultimately enable the development of not only safer but also more efficacious drug delivery systems still remain. To this end, the harmonized integration of researchers from diverse multidisciplinary fields (namely, formulation scientists, cancer pathologists, clinical doctors) is required to foster the development of clinically translatable novel formulations for cancer therapy.

Guest Editors

Prof. Dr. Ana Isabel Torres-Suárez

Department of Pharmaceutics and Food Technology, Complutense University of Madrid, 28040 Madrid, Spain

Dr. Juan Aparicio-Blanco

Department of Pharmaceutics and Food Technology, Faculty of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain

Deadline for manuscript submissions

closed (31 October 2022)



Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/79063

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

